Eribulin in cancer treatment

Umang Swami, Umang Shah, Sanjay Goel

Research output: Contribution to journalReview article

23 Scopus citations

Abstract

Halichondrin B is a complex, natural, polyether macrolide derived from marine sponges. Eribulin is a structurally-simplified, synthetic, macrocyclic ketone analogue of Halichondrin B. Eribulin was approved by United States Food and Drug Administration in 2010 as a third-line therapy for metastatic breast cancer patients who have previously been treated with an anthracycline and a taxane. It has a unique microtubule dynamics inhibitory action. Phase III studies have either been completed or are currently ongoing in breast cancer, soft tissue sarcoma, and non-small cell lung cancer. Phase I and II studies in multiple cancers and various combinations are currently ongoing. This article reviews the available information on eribulin with respect to its clinical pharmacology, pharmacokinetics, pharmacodynamics, mechanism of action, metabolism, preclinical studies, and with special focus on clinical trials.

Original languageEnglish (US)
Pages (from-to)5016-5058
Number of pages43
JournalMarine Drugs
Volume13
Issue number8
DOIs
StatePublished - Aug 1 2015

Keywords

  • Breast cancer
  • E7389
  • EMBRACE
  • Eribulin
  • Halaven<sup>™</sup>
  • Halichondrin B
  • Microtubule inhibitor
  • NSC 707389

ASJC Scopus subject areas

  • Drug Discovery

Fingerprint Dive into the research topics of 'Eribulin in cancer treatment'. Together they form a unique fingerprint.

  • Cite this